Dr. Ashraf S Ibrahim's Lab
@IbrahimLab3
Followers
385
Following
174
Media
21
Statuses
201
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Ashraf S Ibrahim: email: [email protected]
Torrance,CA
Joined January 2019
Happy to see our paper describing the activity and MoA of a humanized MAb (VX-01) against mucormycosis published in Sciences Translational Medicine. This takes us a step closer to clinical testing on the road to provide better care for this lethal fungal infection.
0
1
4
The Lundquist Institute, together with its start-up company @VitalexBioscien, is proud to announce a significant advancement in fungal vaccine research.🔬 Supported by a highly competitive $40 million contract from the NIH’s @NIAIDNews, the team is moving its second-generation,
1
4
7
Honored to welcome @SenBillCassidy to @the_lundquist. I showed him @IbrahimLab3, where we study host–pathogen interactions, develop immunotherapies for mucormycosis, and advance vaccines against drug-resistant infections. Grateful for his support of biomedical research.
1
4
15
IT'S A TWO-FER! A huge congratulations to TLI Investigator @IbrahimLab3 for receiving the 43rd Kuwait Prize by the @KuwaitFAS. This prestigious award honors Kuwaiti and Arab scientists for their exceptional scientific and intellectual contributions on a global scale.🚀 Dr.
0
2
4
Mucormycosis is a fungal infection that causes severe disease and fatality, especially in immunocompromised individuals. While vaccines and immunotherapeutics have been available in combating viral and bacterial infections, approved antifungal immunotherapies are lacking. Thanks
Scientists show that a humanized antibody that targets CotH fungal spore coat proteins can treat #mucormycosis in mice by augmenting host immunity, supporting its translation as one of the first antifungal #immunotherapies. @IbrahimLab3 @the_lundquist
https://t.co/Wr1Oq90Qel
0
2
2
Mucormycosis is a fungal infection that causes severe disease and fatality. “Mucormycosis usually occurs in patients who suffer from weakened immune system, such as patients with poorly controlled diabetes, cancer patients undergoing chemotherapy, and transplant patients,” says
0
5
8
Humanizing Monoclonal Antibodies for Mucormycosis Treatment https://t.co/NaPbRtLJ6K via @contagionlive @the_lundquist @VitalexBioscien
contagionlive.com
Ashraf S. Ibrahim, PhD, details over 20 years of research on a spore-coating protein and the development of VX-01 to block fungal tissue invasion.
1
1
3
Happy to see our paper describing the activity and MoA of a humanized MAb (VX-01) against mucormycosis published in Sciences Translational Medicine. This takes us a step closer to clinical testing on the road to provide better care for this lethal fungal infection.
0
1
4
A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response | Science Translational Medicine
science.org
An anti-CotH humanized IgG1 antibody protects against lethal mucormycosis when given as adjunctive therapy to immunocompromised mice.
0
0
7
🔬✨ National Immunization Awareness Month✨🔬 This August, we spotlight the critical role of vaccines and immunotherapies in our fight against infectious diseases. Learn more about @IbrahimLab3's work and @the_lundquist below: https://t.co/Pik5K4e7GY
instagram.com
0
1
1
That’s a wrap! After 3 weeks in L.A I just have thankful words for the fantastic and welcoming @IbrahimLab3. Loads of learning at @the_lundquist see you later California @BallouLab @MRCcmm #Collaboration #STEM #FungiFriday
1
3
15
@the_lundquist Investigator Ashraf Ibrahim, PhD, has been selected by the Medical Mycology Society of the Americas (MMSA) to receive the 2024 Billy H. Cooper Award for his continuous outstanding achievement in clinical mycology. TLI congratulates Dr Ibrahim for this high honor.
2
4
19
Congrats @kierenamarr @davidrandes Nathan Wiederhold @doctorfungus @IbrahimLab3 Bill Steinbach etc on this achievement!
0
5
16
0
0
12
Vitalex Biosciences, a spinoff start-up company of The Lundquist Institute for Biomedical Innovation, is proud to announce today that its VX-01 monoclonal antibody program targeting the debilitating indication of mucormycosis has been awarded an SBIR Phase 2 grant from NIAID/NIH.
Vitalex Biosciences, a spinoff start-up company of The Lundquist Institute for Biomedical Innovation, is proud to announce today that its VX-01 monoclonal antibody (mAb) program targeting the debilitating indication of mucormycosis has been awarded an SBIR Phase 2 grant from
0
2
15
Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections @IbrahimLab3 @Ana_Alastruey @Nkechi93564130
mdpi.com
Molds are ubiquitous in the environment, and immunocompromised patients are at substantial risk of morbidity and mortality due to their underlying disease and the resistance of pathogenic molds to...
0
7
18
0
2
9
VX01 targets the fungal invasion,CotH3 and is proven in preclinical testing to treat mucormycosis alone or synergistically with FDA-approved antifungal agents.
1
1
2
The award was issued by NIAID Preclinical service (PCS) to select a Research Cell Bank to further the establishment of a Master Cell Bank. Vitalex also recently received a competitive score of 24 on a Phase II SBIR grant.
1
1
1